SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. You have free access to this content1
    Konrad Klinghammer, Jan-Dirk Raguse, Thomas Plath, Andreas E. Albers, Korinna Joehrens, Andre Zakarneh, Bernadette Brzezicha, Annika Wulf-Goldenberg, Ulrich Keilholz, Jens Hoffmann, Iduna Fichtner, A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option, International Journal of Cancer, 2015, 136, 12
  2. 2
    Ki-Yeol Kim, Xianglan Zhang, In-Ho Cha, Identification of human papillomavirus status specific biomarker in head and neck cancer, Head & Neck, 2015, 37, 9
  3. 3
    Massimo Re, Artan Çeka, Corrado Rubini, Luigi Ferrante, Antonio Zizzi, Federico M. Gioacchini, Michele Tulli, Liana Spazzafumo, Stefano Sellari-Franceschini, Antonio D. Procopio, Fabiola Olivieri, MicroRNA-34c-5p is related to recurrence in laryngeal squamous cell carcinoma, The Laryngoscope, 2015, 125, 9
  4. 4
    Dominik Riss, Johannes Pammer, Matthaeus C. Grasl, Alexandra Kaider, Sven Schneider, Boban M. Erovic, No evidence for desmocollin 3 to serve as a prognostic marker in primary radiotherapy of head and neck cancer, Wiener klinische Wochenschrift, 2015, 127, 1-2, 24

    CrossRef

  5. 5
    Mitsuo Goto, Nobuhiro Hanai, Taijiro Ozawa, Hitoshi Hirakawa, Hidenori Suzuki, Ikuo Hyodo, Takeshi Kodaira, Tetsuya Ogawa, Yasushi Fujimoto, Akihiro Terada, Hisakazu Kato, Yasuhisa Hasegawa, Prognostic factors and outcomes for salvage surgery in patients with recurrent squamous cell carcinoma of the tongue, Asia-Pacific Journal of Clinical Oncology, 2015, 11, 3
  6. 6
    Benjamin L. Witt, Daniel J. Albertson, Margaret G. Coppin, Christian F. Horrocks, Melissa Post, H. Evin Gulbahce, Use of In Situ Hybridization for HPV in Head and Neck Tumors: Experience from a National Reference Laboratory, Head and Neck Pathology, 2015, 9, 1, 60

    CrossRef

  7. 7
    Andrew P. Stein, Adam D. Swick, Molly A. Smith, Grace C. Blitzer, Robert Z. Yang, Sandeep Saha, Paul M. Harari, Paul F. Lambert, Cheng Z. Liu, Randall J. Kimple, Xenograft assessment of predictive biomarkers for standard head and neck cancer therapies, Cancer Medicine, 2015, 4, 5
  8. 8
    Heike Scheithauer, Claus Belka, Kirsten Lauber, Udo S Gaipl, Immunological aspects of radiotherapy, Radiation Oncology, 2014, 9, 1, 185

    CrossRef

  9. 9
    Jennifer L. Hunt, Leon Barnes, James S. Lewis, Magdy E. Mahfouz, Pieter J. Slootweg, Lester D. R. Thompson, Antonio Cardesa, Kenneth O. Devaney, Douglas R. Gnepp, William H. Westra, Juan P. Rodrigo, Julia A. Woolgar, Alessandra Rinaldo, Asterios Triantafyllou, Robert P. Takes, Alfio Ferlito, Molecular diagnostic alterations in squamous cell carcinoma of the head and neck and potential diagnostic applications, European Archives of Oto-Rhino-Laryngology, 2014, 271, 2, 211

    CrossRef

  10. 10
    M. Re, A. Zizzi, L. Ferrante, D. Stramazzotti, G. Goteri, F. M. Gioacchini, F. Olivieri, G. Magliulo, C. Rubini, p63 and Ki-67 immunostainings in laryngeal squamous cell carcinoma are related to survival, European Archives of Oto-Rhino-Laryngology, 2014, 271, 6, 1641

    CrossRef

  11. 11
    Thorsten Fuereder, Judith Stift, Irene Kuehrer, Nadja Stranzl, Doris Hoeflmayer, Gabriela Kornek, Werner Scheithauer, Response to GEMOX plus erlotinib in pancreatic cancer is associated with ERCC1 overexpression, European Journal of Clinical Investigation, 2014, 44, 10
  12. 12
    S Postel-Vinay, I Bajrami, L Friboulet, R Elliott, Y Fontebasso, N Dorvault, K A Olaussen, F André, J-C Soria, C J Lord, A Ashworth, A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer, Oncogene, 2013, 32, 47, 5377

    CrossRef

  13. 13
    Stephen B. Keysar, David P. Astling, Ryan T. Anderson, Brian W. Vogler, Daniel W. Bowles, J. Jason Morton, Jeramiah J. Paylor, Magdalena J. Glogowska, Phuong N. Le, Justin R. Eagles-Soukup, Severine L. Kako, Sarah M. Takimoto, Daniel B. Sehrt, Adrian Umpierrez, Morgan A. Pittman, Sarah M. Macfadden, Ryan M. Helber, Scott Peterson, Diana F. Hausman, Sherif Said, Ted H. Leem, Julie A. Goddard, John J. Arcaroli, Wells A. Messersmith, William A. Robinson, Fred R. Hirsch, Marileila Varella-Garcia, David Raben, Xiao-Jing Wang, John I. Song, Aik-Choon Tan, Antonio Jimeno, A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins, Molecular Oncology, 2013, 7, 4, 776

    CrossRef

  14. 14
    Mohammad Saki, Mahmoud Toulany, H. Peter Rodemann, Acquired resistance to cetuximab is associated with the overexpression of Ras family members and the loss of radiosensitization in head and neck cancer cells, Radiotherapy and Oncology, 2013, 108, 3, 473

    CrossRef

  15. 15
    Jan B Vermorken, Jan Stöhlmacher-Williams, Irina Davidenko, Lisa Licitra, Eric Winquist, Cristian Villanueva, Paolo Foa, Sylvie Rottey, Krzysztof Skladowski, Makoto Tahara, Vasant R Pai, Sandrine Faivre, Cesar R Blajman, Arlene A Forastiere, Brian N Stein, Kelly S Oliner, Zhiying Pan, Bruce A Bach, Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial, The Lancet Oncology, 2013, 14, 8, 697

    CrossRef

  16. 16
    Diana V Messadi, Diagnostic aids for detection of oral precancerous conditions, International Journal of Oral Science, 2013, 5, 2, 59

    CrossRef

  17. 17
    Miroslaw J Szczepanski, Theresa L Whiteside, Elevated PRAME expression: what does this mean for treatment of head and neck squamous cell carcinoma?, Biomarkers in Medicine, 2013, 7, 4, 575

    CrossRef

  18. 18
    Juliana Bonilla-Velez, Edmund A. Mroz, Rebecca J. Hammon, James W. Rocco, Impact of Human Papillomavirus on Oropharyngeal Cancer Biology and Response to Therapy, Otolaryngologic Clinics of North America, 2013, 46, 4, 521

    CrossRef

  19. 19
    Feng-Ying Li, Xiao-Bin Ren, Xin-You Xie, Jun Zhang, Meta-analysis of Excision Repair Cross-complementation Group 1 (ERCC1) Association with Response to Platinum-based Chemotherapy in Ovarian Cancer, Asian Pacific Journal of Cancer Prevention, 2013, 14, 12, 7203

    CrossRef

  20. 20
    Miroslaw J. Szczepanski, Albert B. DeLeo, Michał Łuczak, Marta Molinska-Glura, Jan Misiak, Bronislawa Szarzynska, Grzegorz Dworacki, Mariola Zagor, Natalia Rozwadowska, Maciej Kurpisz, Antoni Krzeski, Aleksandra Kruk-Zagajewska, Tomasz Kopec, Jacek Banaszewski, Theresa L. Whiteside, PRAME expression in head and neck cancer correlates with markers of poor prognosis and might help in selecting candidates for retinoid chemoprevention in pre-malignant lesions, Oral Oncology, 2013, 49, 2, 144

    CrossRef